Concepedia

Jie Liu

JL

Statistics

Publications

19

Citations

990

H-Index

16

Active since

2011

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Pfizer (United States)

University of Tennessee Health Science Center

University of Toronto

Translational Research Institute for Metabolism and Diabetes

Jie Liu is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, pharmacology, and clinical pharmacology.

ORCID

Publications per year

2011–2024

19

Publications

19

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The <scp>VERTIS SITA2</scp> placebo‐controlled randomized study

Samuel Dagogo‐Jack, Jie Liu, Roy Eldor et al. · Diabetes Obesity and Metabolism · 2017 · 160 citations · Full text

, , +11

Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables

Linong Ji, Juming Lu, Xiaohui Guo et al. · BMC Public Health · 2013 · 146 citations · Full text

, , +17

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

Priscilla Hollander, Jie Liu, Julie Hill et al. · Diabetes Therapy · 2017 · 108 citations · Full text

, , +17

Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling

Yuze Zhang, Xiaoyan Lin, Yong Chu et al. · Cardiovascular Diabetology · 2021 · 100 citations · Full text

, , +17

Structural selectivity of human SGLT inhibitors

Charles S. Hummel, Chuan Lü, Jie Liu et al. · American Journal of Physiology-Cell Physiology · 2011 · 92 citations · Full text

, , +15

1–5 of 19